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therapeutic conclusions. Colonization with fungi has been
identiﬁed as an independent risk factor for invasive myco-
sis. In addition to colonization with a single species, the
combination of different fungal species may be of interest.
Methods: In a prospective study we analyzed samples
taken from 411 patients after admission to our ICU. Swabs
from nostril, throat and anus and specimens of tracheal
secretions and urine were taken and cultured on CHROM-
Agar.
Results: Positive results were found in 798 (42.7%) of
all 1868 samples. Of these, 618 were positive for a single
species, 158 for two species, and 22 for three species. Con-
cerning distribution of species, we found Candida albicans
in 69.3%, Candida glabrata in 34.8% and Candida tropi-
calis in 8.1% of all positive specimens. In 90 cases, cultures
grew Candida albicans together with Candida glabrata, in 23
cases, Candida albicans together with Candida tropicalis, in
12 cases, Candida albicans together with Candida glabrata
and Candida tropicalis. Most frequently, a mixed coloniza-
tion was detected from throat swabs (74 mixed, out of 281
positive cultures, 26.3%), followed by tracheal secretions
(35 mixed, out of 153 positive cultures, 22.9%) and anal
swabs (48 mixed, out of 235 positive cultures, 20.4%). In con-
trast, a mixed colonization was signiﬁcantly less frequent in
nasal swabs (18 mixed, out of 136 positive cultures, 13.2%)
and in urine (5 mixed, out of 56 positive cultures, 8.9%).
Conclusion: A large proportion of samples showed growth
of yeasts. Out of culturally positive, in 22.6% were found
more than one species. Colonization with more than one
species was found to be signiﬁcantly more frequent in
throat, trachea and anus compared to nose and urine.
doi:10.1016/j.ijid.2010.02.1744
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Background: In recent years a shift towards candida non
albicans has been reported from candidemia trials. A species
shift in candidemia is important, since newer guidelines
favor upfront echinocandins containing an economic bur-
den. This has to be balanced with medical needs. Trends
of epidemiology outside of controlledl trials are therefore
of particular interest.
We analyzed all candida isolates from ﬁve Munich teach-
ing hospitals (3500 beds). The objective was to compare all
candida isolates and all candidemia eps in 2008 and 09 with
the previous 2ys (data in brackets).
Methods: Between 01/08 and 10/09 a total of 15258 can-
dida isolates were detected. No routine azole prophylaxis
was given beside high risk cancer pts.There was no hint for
a seasonal cluster during the study periods.
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Results: While 64,20% (64.9%) were C. albicans, 7,5%
7.8%) were C. glabrata ahead of C. tropicalis with 4,7
4.6%), while in 1,74% C. krusei was detected. 384 isolates
ere obtained from two hemato-oncology units with C. albi-
ans 52, 3% (80.5%) ahead of C. glabrata 8,1% (7.8%), C.
ropicalis 5,4% (4.7%) and C. krusei (1.9%). A total of 148
solates were detected from blood cultures. C. albicans was
ound to be less common in candidemia 57,5% (58.9%), but
ominated far ahead of C. glabrata 17,1% (20.9%), C. trop-
calis 6,8% (7.0%), C. parapsilosis 4,8% (5.4%) and C. krusei
,7% (3.1%). 28.6% of candidemia eps was by C glabrata in
ancer pts in 2008 an 09.
Conclusion: Although a shift towards C. non albicans has
een described elsewhere, our study indicated C. albicans
emains the leading species. No further shift to C. glabrata
nd C. tropicalis has been observed within the last 4 years.
f candida is found, C. glabrata is detected about 2.3-fold
ore often and accounts for 17% of candidemia eps, with
n even 3.8-fold higher risk in cancer pts. Echinocandins,
ewer azoles and lipid AmB therefore seem to be justiﬁed
or upfront candidemia Rx, in particular cancer and those
ts with an unstable clinical condition.
oi:10.1016/j.ijid.2010.02.1745
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subgroup of patients with ulcerative colitis, Crohn’s dis-
ase, GI Behcet, and GI tuberculosis: Correlations with
isease duration, activity, and extension
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Background: Clinical utility of serological markers in
nﬂammatory bowel disease (IBD) diagnosis and differen-
iating is controversial. Recently ASCA has been found to
ave some correlation with the complication and recurrent
urgery rate Our aim was to seek for correlations between
SCA levels and disease duration, extension, activity, CRP
evels, and use of immmunosupressive therapy
Methods: A total of 41 consecutive patients (16 UC,
0CD, 3 GI BD, and 2 GI Tb; 34 women, 7 male) were ana-
yzed regarding ASCA IgG levels with anti-ASCA IgG ELISA kit
Euroimmune, Lübeck, Germany), the cut-off value being
5 U/ml. Disease activity was assessed using SEO for UC and
DAI for CD, GI BD, and GI Tb patients, respectively. Addi-
ionally, a simpliﬁed endoscopic extension score was used
y dividing the colon into six equal units and accepting ileal
nvolvement as an additional unit in an ordinal manner. SPSS
5 for Windows is used for data collection and are expressed
s means, with SD of the mean calculated when appropriate.
orrelations were sought using Pearson’s and Spearman’s
orrelation coefﬁcient and multivariate analysis was per-
ormed by using a stepwise regression model. p < 0.05 was
egarded as signiﬁcance.
